NuCana (NCNA) Stock Price, News & Analysis

Company Overview

NuCana plc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company applies its ProTide technology platform to existing nucleoside analogues, with the goal of improving their delivery into tumor cells, increasing anticancer activity and overcoming mechanisms of drug resistance.

NuCana’s pipeline has included Acelarin (NUC-1031), a ProTide-based version of gemcitabine investigated in several solid tumors, including pancreatic, biliary tract and ovarian cancers. The company has also developed NUC-3373, a ProTide analogue of 5-fluorouracil, and NUC-7738, an investigational cancer therapy derived from a nucleoside analogue. These candidates have been evaluated in clinical studies, but NuCana has not reported a marketed commercial product.

NuCana was founded in 2008 and is headquartered in Edinburgh, Scotland. Its drug-development activities have involved clinical research in the United Kingdom, the United States and other international markets. The company has been led by Hugh Griffith, its chief executive officer and a co-founder, alongside a management and scientific team focused on oncology drug development.

Key Stats

• Today's Range: $1.07 to $1.18
• 50-Day Range: $1.06 to $1.76
• 52-Week Range: $0.95 to $6.17
• Volume: 67,437 shs
• Average Volume: 251,994 shs
• Market Capitalization: $4.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

NuCana Stock Analysis - MarketRank™

NuCana scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

NuCana has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

NuCana has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NuCana is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NuCana is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NuCana has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.49% of the float of NuCana has been sold short.

Short Interest Ratio / Days to Cover

NuCana has a short interest ratio ("days to cover") of 0.31, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NuCana has recently decreased by 6.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NuCana does not currently pay a dividend.

Dividend Growth

NuCana does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

NuCana has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for NuCana this week, compared to 1 article on an average week.

MarketBeat Follows

3 people have added NuCana to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NuCana insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:NCNA
• CIK: 1709626
• Web: www.nucana.com
• Phone: 441313571111
• Fax: N/A
• Employees: 11
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): ($3.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.71 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.90%
• Return on Assets: -33.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.73
• Quick Ratio: 4.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.71 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 4,160,000
• Free Float: 2,863,000
• Market Cap: $4.58 million
• Optionable: Not Optionable
• Beta: 2.30